Atomwise

Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. We've partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals. Recently, Atomwise raised $45 million from leading venture capital firms to support the development and application of its AI technology.